Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance Study of HDM1002 in Healthy Chinese Subjects
NCT06576401Phase 1Recruiting
- Sponsor
- Huadong Medicine
- Start
- Aug 2024
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of conveglipron in type 2 diabetes mellitus (T2DM) and obesity, sponsored by Huadong Medicine. Primary endpoints: Total recovery of HDM1002 radioactivity in urine and feces at Day 11, Metabolite profiling/identification in plasma, urine, and feces at Day 11 and 6 more. Started Aug 2024; status: recruiting.
02
Drugs
conveglipron
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NCT06576401.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06576401.